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S U M M A R Y
Background: The clinical characteristics of internal medicine ward (IMW) patients with candidemia are
unclear. The aim of this study was to deﬁne the clinical characteristics of candidemic IMW patients and
to study the incidence, species distribution, and outcomes of these patients compared to surgical and
intensive care unit (ICU) candidemic patients.
Methods: A retrospective cohort of candidemic patients in IMWs, general surgery wards, and an ICU at
Beilinson Hospital during the period 2007–2014 was analyzed.
Results: A total of 118 patients with candidemia were identiﬁed in six IMWs, two general surgery wards,
and one ICU in the hospital. Candida albicans was the leading causative agent (41.1%). Higher proportions
of Candida parapsilosis and Candida tropicalis isolates were observed in the IMW patients. IMW patients
were signiﬁcantly older, with poorer functional capacity, and had more frequently been exposed to
antibiotic therapy within 90 days, in particular b-lactam–b-lactamase inhibitor combinations and
cephalosporins. At onset of candidemia, a signiﬁcantly lower number of IMW patients were
mechanically ventilated (p < 0.01); these patients did not have central line catheters comparable to
ICU and surgical patients (p < 0.001). They were less likely to receive adequate antifungal therapy within
48 h, and this was the only signiﬁcant predictor of survival in these patients (p = 0.028): hazard ratio 3.7
(95% conﬁdence interval 1.14–12.5) for therapy delayed to >48 h.
Conclusions: IMW candidemic patients account for a substantial proportion of candidemia cases and
have unique characteristics and high mortality rates.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Invasive candidiasis is the most common fungal infection
among hospitalized patients. Epidemiological studies over the past
decade have identiﬁed Candida species as the fourth most common
cause of nosocomial bloodstream infection (BSI), although these
reports were mainly for critical care units.1 Despite the advances in
antifungal therapy, candidemia continues to contribute to greater
mortality, prolonged hospitalization, and increased costs of care.2,3
Candidemia has been studied extensively worldwide.3–8 It has* Corresponding author.
E-mail address: noaeliakim@gmail.com (N. Eliakim-Raz).
1 These authors are contributed equally to this work.
http://dx.doi.org/10.1016/j.ijid.2016.09.018
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).been well described in speciﬁc populations, including surgical
patients, intensive care unit (ICU) patients, mechanically ventilat-
ed patients, and those with central venous catheters (CVC),
indwelling urinary catheters, and exposure to total parenteral
nutrition (TPN).4,5,9,10 Data on candidemia in non-surgical, non-
ICU patients remain scarce. The diagnosis of candidemia in internal
medicine wards (IMWs) is often delayed or overlooked, and
consequently these patients have worse outcomes compared to
candidemic surgical or ICU patients.
A shift in etiology of candidemia has been reported over the past
10 years. While Candida albicans is still considered the most
common species causing candidemia, increasing rates of Candida
tropicalis, Candida parapsilosis, Candida glabrata, and Candida krusei
in candidemia have been reported worldwide.5,11–14 Candidemia
rates and the distribution of Candida species vary geographically.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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species distribution, and antifungal drug susceptibility proﬁles in
every country.6–8,12,15–20The primary objective of this study was to
evaluate the clinical characteristics of candidemia in patients
admitted to IMWs compared to patients in surgical wards and the
ICU. Secondary objectives were to evaluate the incidence of
candidemia among IMW patients compared to surgical and ICU
patients, to identify the species distribution and antifungal
susceptibility patterns over the years, and to evaluate in-hospital
and overall mortality rates.
2. Materials and methods
2.1. Subjects and study design
All consecutive candidemic adult patients (>18 years) hospital-
ized in six IMWs, two surgical wards, and one ICU, diagnosed
between January 2007 and December 2014, were included in this
retrospective observational study. The study was conducted at
Rabin Medical Center, Beilinson Hospital in Petah Tikva, Israel. This
is a 900-bed primary and tertiary care, university-afﬁliated hospital
that serves an urban, elderly population of about 400 000 as a ﬁrst-
line facility. It is also a referral center for several hospitals in the
vicinity. The hospital has four main ICUs and also small ICUs in
which patients undergo mechanical ventilation within the six
IMWs and two surgical departments. Data regarding demographic
and clinical characteristics, treatment, and clinical outcomes were
collected from the patient medical records.
Adequate antifungal treatment was considered when the
Candida isolate was susceptible to the administered antifungal
therapy and treatment started within 48 h from the ﬁrst blood
culture performed.4 Finally, a comparison was made of all
dependent variables between candidemic patients in the IMWs,
general surgery wards, and ICU.
2.2. Microbiological methods
The diagnosis of candidemia was deﬁned as the growth of
Candida species in one or more blood cultures in a patient with
temporally related clinical signs and symptoms of infection. Each
patient was included once; only the ﬁrst episode of candidemia
was included for each patient. Isolates were detected in blood
cultures using several tests, including CHROMagar Candida and the
germ tube assay for all suspected C. albicans isolates, VITEK II, and
the API ID 32 C (bioMe´rieux, Marcy l’Etoile, France). The in vitro
activity of the antifungal agents was measured using the Etest (AB
Biodisk, Solna, Sweden) in accordance with the manufacturer’s
instructions (Appendix 1).
2.3. Statistical analysis
The incidence of candidemia was calculated per 1000 hospital
admissions, and 95% conﬁdence intervals (CI) were estimated
assuming a Poisson distribution of cases. The distribution of
Candida species was analyzed according to the study period and
hospital ward. All dichotomous variables, expressed as the number
and percentage, were compared by Chi-square test (for more than
two groups) or Fisher’s exact test (for two groups). Continuous
variables, expressed as the mean  standard deviation or as the
median and interquartile range (IQR, 25th–75th percentiles), were
compared using analysis of variance (ANOVA). Variables found to be
statistically signiﬁcant in the descriptive analysis and/or those with
clinical relevance based on previous studies showing the importance
of these covariates on mortality were analyzed according to 30-day
mortality.4 A planned multivariable analysis was conducted for
variables found to be statistically signiﬁcant in the univariateanalysis. Results were expressed as hazard ratios (HR) and 95% CI.
Statistical signiﬁcance was established using a probability level of 5%
(p < 0.05). The statistical analysis was performed using SAS software,
version 9.4 (SAS Institute, Cary, NC, USA).
3. Results
A total of 106 consecutive patients with candidemia were
identiﬁed during the study period; 51 patients were hospitalized in
the six IMWs, 31 in the two surgical departments, and 24 patients
in the ICU.
3.1. Epidemiology
The overall incidence rate was 0.61 episodes/1000 hospital
admissions (range 0.42–0.92/1000 hospital admissions, 95% CI
0.5–0.7). The incidence rate according to hospital ward was
0.34 episodes/1000 hospital admissions (95% CI 0.2–0.5) in the
IMWs, 0.82 episodes/1000 hospital admissions (95% CI 0.5–1.1) in
the surgery wards, and 7.35 episodes/1000 hospital admissions
(95% CI 4.9–9.8) in the ICU. These incidence rates are comparable
with previously published data in Israel.9
During the study period, C. albicans was the leading causative
agent of candidemia (52 patients, 41.1%), followed by C. glabrata
(28 patients, 23.7%), C. parapsilosis (18 patients, 15.2%), and C.
tropicalis (16 patients, 13.6%); other Candida species included C.
krusei in the ICU, Candida lusitaniae, Candida lipolytica, and Candida
rugosa (one isolate of each, in four (7.6%) patients) (Fig. 1A). There
was a higher proportion of C. glabrata isolates in patients
hospitalized in the surgery wards and ICU (Fig. 1B), while there
were higher proportions of C. parapsilosis and C. tropicalis isolates
in the IMW patients. No signiﬁcant difference in the proportion of
C. albicans between the IMW patients and the ICU and surgery
ward patients was found (Fig. 1C). Over the years, the percentage of
C. albicans decreased from 53.8% to 35.3% and the percentage of C.
glabrata increased from 7.7% to 29.4%. Trends in the proportions of
other isolates could not be demonstrated.
3.2. Baseline and clinical characteristics
Patient baseline and clinical characteristics were available for
106 of the 118 patients. These characteristics are summarized in
Tables 1 and 2. Comparing candidemic patients in the IMWs with
those in the surgery wards and ICU, IMW patients were
signiﬁcantly older: mean age 75  11.7 years vs. 65.9  15.8 and
57.7  16.4 years in the surgery wards and ICU, respectively
(p < 0.0001). The median age was 76 (IQR 47–95) years in the IMWs,
67 (IQR 19–95) years in the surgery wards, and 62.5 (IQR 20–81) years
in the ICU.
IMW patients had poorer functional capacity, were more
commonly admitted from a nursing home, and had more
frequently been exposed to antibiotic therapy within 90 days, in
particular b-lactam–b-lactamase inhibitor combinations and
cephalosporins. The mean Charlson score of IMW patients was
4.4  2.3, which was signiﬁcantly higher than the mean score of
surgery ward patients (3.1  2) and ICU patients (3  2) (p < 0.006).
The median Charlson score was 4 (IQR 0–11) in the IMW patients, 2
(IQR 0–8) in the surgery ward patients, and 3 (IQR 0–6) in the ICU
patients.
As expected, previous abdominal surgery and parenteral
nutrition were signiﬁcantly more frequent in surgery ward and
ICU patients. At the onset of candidemia, a signiﬁcantly lower
number of IMW patients were mechanically ventilated (p < 0.01);
these patients did not have central line catheters comparable to
ICU and surgical patients (p < 0.001) and had signiﬁcantly more
thrombocytopenia than surgical patients (p < 0.01). Interestingly,
Fig. 1. Overall distribution of Candida species isolates during the study period (A),
according to the ward (B) and time period (C).
N. Eliakim-Raz et al. / International Journal of Infectious Diseases 52 (2016) 49–54 51only 27 (52.9%) candidemic patients in the IMWs received
antifungal therapy at any time after identiﬁcation, compared to
26 (83.8%) patients in the surgical departments and 16 (66.6%)
patients in the ICU. IMW candidemic patients were also less likely
to receive adequate antifungal therapy within 48 h, with 41 (80.3%)
patients treated at >48 h or not treated at all, compared to 19
(61.2%) patients in the surgical wards and nine (37.5%) patients in
the ICU. The frequency of removing indwelling catheters was also
signiﬁcantly lower in the IMWs than in the surgical wards and ICU.
Out of all patients with C. glabrata (n = 28), 11 were treated
deﬁnitively with ﬂuconazole according to the susceptibility
pattern. One candidemic patient with a C. krusei isolate was
treated empirically with ﬂuconazole before species identiﬁcation
of the yeast in blood culture. The antifungal agent was not changed
because the ﬁnal identiﬁcation was available only after the
patient’s death. Out of all patients with C. parapsilosis (n = 18),
12 were treated adequately with ﬂuconazole according to the
susceptibility pattern.
The crude 30-day mortality rate was highest in ICU patients
(75%), followed by IMW patients (62.7%), and was lowest for
surgical ward patients (38.7%) (p = 0.01). The crude 90-day rate did
not differ signiﬁcantly between groups (Table 3).
On univariate analysis, variables signiﬁcantly associated with
30-day all-cause mortality were the admitting hospital ward,
removal of indwelling catheters, and time to adequate antifun-
gal therapy (Table 4). In a multivariate regression model of theabove-mentioned variables, adequate antifungal therapy within
48 h was the only signiﬁcant predictor of survival (Table 5).
Resistance rates to antifungal therapy are reported in Table 6.
4. Discussion
In this study, the epidemiology, species distribution, antifungal
susceptibility, and clinical outcomes of candidemia in patients
hospitalized in IMWs compared to patients hospitalized in general
surgery wards and an ICU are reported. An overall incidence rate of
0.61 episodes/1000 hospital admissions was found, corresponding
to incidence rate reports of 0.8–2.5 episodes/1000 hospital
admissions in recent studies conducted in Europe and reports
from large multinational studies.13,14,21 A higher incidence rate of
candidemia in IMW patients compared to general surgery ward
patients was not found in this study (0.34 vs. 0.82 episodes/1000
hospital admissions, respectively), as reported recently in a similar
tertiary hospital in Europe.21
Following variations in candidemia rate and species distribu-
tion, C. albicans was shown to be the overall leading cause of
Candida BSI, with a decreasing incidence ranging from 52.8% to
35.5% during the study period. C. glabrata was the second leading
cause of candidemia; an increase in this species over the past
decade was found compared to a previous report from the same
institution.17 C. parapsilosis and C. tropicalis demonstrated a small
decrease in rates and together with C. glabrata represent a
previously described worldwide trend towards non-C. albicans
isolates.1,12,14,15 A high rate of C. glabrata in surgery and ICU
patients compared with IMW patients may suggest selection
pressure from ﬂuconazole prophylaxis in at-risk surgical
patients.16 The reasons for the emergence of non-albicans Candida
species are not completely understood, but some medical
conditions may consistently impact the risk of developing
candidemia due to non-albicans Candida species.12,15 Resistance
to antifungal therapy was high in this study. Overall ﬂuconazole
resistance was the highest in C. parapsilosis (11.1%) and C. glabrata
(10.7%) isolates; in the latter, ﬂuconazole resistance rates actually
decreased in the institution over the past decade.
Baseline and clinical characteristics of candidemic IMW patients
compared to surgical ward and ICU patients are described in
Table 1. It was found that prior antibiotic therapy within 90 days
was signiﬁcantly more prevalent in IMW patients, speciﬁcally b-
lactam–b-lactamase inhibitor combinations and cephalosporins. A
signiﬁcantly lower number of IMW patients were mechanically
ventilated at the onset of candidemia; these patients did not have
central line catheters in place compared to ICU and surgical patients
and had signiﬁcantly more thrombocytopenia than surgical
patients. In IMW patients, carbapenems and cephalosporins were
the most commonly used antibiotics at the onset of candidemia. An
Israeli candidemia study group recently demonstrated that infec-
tion with ﬂuconazole-resistant isolates was associated with
previous exposure to carbapenems, trimethoprim–sulfamethoxa-
zole, clindamycin, and colistin, suggesting that IMW candidemic
patients are at increased risk of non-adequate antifungal therapy.
However, increased resistance rates to ﬂuconazole were not found
in IMW vs. ICU or surgical ward patients.
The crude 30-day mortality rate in IMW patients (62.7%) was
high and second only to ICU patients (75%). The 30-day mortality
rate was also higher than originally reported by Bassetti et al.
(50.4%),4 despite a larger proportion of patients being treated
adequately within 48 h in the present study (19.6% vs. 7.5%). The
proportion of IMW patients who were not treated was very high in
this study (41.1%); the majority of them died before the
identiﬁcation of yeast in blood cultures was made (66.6%).
Adjusting the no-treatment rate for patients who were alive when
the identiﬁcation of yeast in blood cultures was made, comparable
Table 1
Baseline characteristics of candidemic patients hospitalized in internal medicine wards compared with those in the surgery wards and intensive care unit
Variable IMWs n = 51 Others n = 55 p-Value
Surgery n = 31 ICU n = 24
Age, years, mean (SD) 75.4 (11.7) 65.9 (15.8) 57.7 (16.4) <0.01
Sex, male, n (%) 22 (43.1) 16 (51.1) 8 (33.3) 0.39
BMI, kg/m2, mean (SD) 26.1 (7.2) 23 (1.6) 24 (5.5) 0.53
Assistance in ADL, n (%) 41 (80.3) 13 (41.9) 4 (16.6) <0.01
Nursing home prior to hospitalization, n (%) 23 (45.1) 7 (22.5) 4 (16.6) 0.13
Prior hospitalization in 90 days, n (%) 33 (64.7) 18 (58.0) 10 (41) 0.16
Duration, days, mean (SD) 21.3 (18.8) 20.9 (22.8) 21 (28.1) 0.99
Antibiotic therapy in prior 90 days, n (%) 28 (54.9) 10 (32.2) 5 (20.8) <0.05
Charlson score, mean (SD) 4.4 (2.3) 3.1 (2) 3 (2) <0.01
Solid organ transplant recipient, n (%) 2 (3.9) 0 7 (29.1) <0.01
Dialysis, n (%) 4 (7.8) 1 (3.2) 2 (8.3) 0.66
Pressure ulcer, n (%) 26 (51.0) 7 (12.6) 0 <0.01
Abdominal surgery in 90 days, n (%) 1 (1.9) 20 (64.5) 12 (50) <0.01
Parenteral nutrition, n (%) 1 (1.9) 17 (54.8) 6 (25) <0.01
Central line catheter, n (%) 19 (37.2) 19 (61.2) 23 (95.8) <0.01
Permacath/PICC line, n (%) 8 (15.6) 12 (38.7) 3 (12.5) <0.01
Urinary catheter, n (%) 28 (54.9) 15 (48.3) 19 (79.1) <0.01
Mechanical ventilation, n (%) 21 (41.1) 9 (29) 22 (91.6) <0.01
Steroid therapy, n (%) 1 (1.9) 1 (3.2) 3 (12.5) 0.12
Cytotoxic treatment, n (%) 7 (13.7) 1 (3.2) 1 (4.1) 0.17
Biological therapies, n (%) 2 (3.8) 0 1 (4.1) 0.52
Chronic renal failure, n (%) 20 (39.2) 8 (25.8) 6 (25) 0.31
Myocardial infarction, n (%) 19 (37.2) 4 (12.9) 2 (8.3) <0.01
Heart failure, n (%) 18 (35.2) 1 (3.2) 1 (4.1) <0.01
Peripheral vascular disease, n (%) 11 (21.5) 0 2 (8.3) <0.05
Cerebrovascular disease, n (%) 15 (29.4) 3 (9.6) 3 (12.5) 0.05
Dementia, n (%) 11 (21.5) 2 (6.4) 0 <0.05
Chronic lung disease, n (%) 10 (19.6) 4 (12.9) 2 (3.2) 0.41
Diabetes mellitus, n (%) 22 (43.1) 8 (25.8) 8 (33.3) 0.27
Solid tumor, n (%) 7 (13.7) 15 (48.3) 3 (12.5) <0.01
Liver disease, n (%) 6 (11.7) 1 (3.2) 6 (25) 0.05
IMW, internal medicine ward; ICU, intensive care unit; SD, standard deviation; BMI, body mass index; ADL, activities of daily living; PICC, peripherally inserted central
catheter.
Table 2
Clinical characteristics of candidemic patients hospitalized in internal medical wards compared with those in the surgery ward and intensive care unit
Variable IMWs n = 51 Others n = 55 p-Value
Surgery n = 31 ICU n = 24
Duration of hospital stay, days, mean (SD) 26.2 (32.4) 61.2 (58.9) 48.2 (56.5) <0.01
Antibiotic therapy in current hospitalization, n (%) 50 (98) 30 (96.7) 24 (100) 0.585
Duration of current antibiotic therapy, days, mean (SD) 19.6 (17.4) 28.8 (18.2) 26.3 (13.8) <0.05
Antibiotic therapy by agent in current hospitalization, n (%)
Penicillin 4 (7.8) 2 (6.4) 5 (20.8) 0.158
Penicillin and b-lactamase inhibitor 27 (25.9) 20 (64.5) 16 (66.6) 0.418
Cephalosporin 36 (70.5) 22 (70.9) 9 (37.5) <0.05
Carbapenems 12 (23.5) 8 (25.8) 14 (58.3) <0.01
Macrolide 2 (3.9) 0 2 (8.3) 0.273
Aminoglycosides 10 (19.6) 4 (12.9) 2 (8.3) 0.410
Quinolones 6 (11.7) 7 (22.5) 7 (29.1) 0.163
Metronidazole 15 (29.4) 20 (64.5) 9 (37.5) <0.01
Vancomycin 24 (47) 10 (32.2) 13 (54.1) 0.231
Colistin 4 (7.8) 4 (12.9) 5 (20.8) 0.275
Others 7 (13.7) 3 (9.6) 3 (12.5) 0.862
Body temperature <36 or >38 8C, n (%) 27 (52.9) 17 (54.8) 17 (70.8) <0.01
Systolic blood pressure <90 mmHg, n (%) 7 (13.7) 3 (9.6) 2 (8.3) 0.744
Leukocytosis or leukopenia, n (%) 32 (62.7) 19 (61.2) 18 (75) 0.257
Absolute neutrophil count <0.5 109/l , n (%) 3 (5.8) 12 (38.7) 3 (12.5) <0.01
Thrombocytopenia, PLT <150 109/l , n (%) 13 (25.4) 4 (12.9) 18 (75) <0.01
C-reactive protein, mg/dl, mean (SD) 15 (11.5) 17.1 (8.6) 19.4 (11.4) 0.472
Time from culture to identiﬁcation <48 h, n (%) 19 (37.2) 21 (67.7) 13 (54.1) <0.05
Concomitant bacteremia, n (%) 22 (43.1) 15 (48.3) 7 (29.1) 0.338
Identical Candida spp isolates at other sites, n (%)
Sputum culture 0 3 (9.7) 3 (12.5) 0.082
BAL culture 1 (1.9) 0 0 0.850
Urine culture 9 (17.6) 3 (9.6) 2 (8.3) 0.647
Vascular line culture 2 (3.8) 11 (35.4) 6 (25) <0.05
Adequate antifungal therapy 10 (19.6) 12 (38.7) 15 (62.5) <0.05
Removal of indwelling catheters, n (%) 11 (21.5) 19 (61.2) 9 (37.5) <0.01
IMW, internal medicine ward; ICU, intensive care unit; SD, standard deviation; PLT, platelets; BAL, bronchoalveolar lavage.
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Table 3
Crude mortality rates for candidemia in the hospital wards
Mortality IMW General surgery ICU Overall p-Value
30-day mortality rate, n (%) 32 (62.7) 12 (38.7) 27 (75) 71 (60.1) 0.011
90-day mortality rate, n (%) 39 (76.4) 20 (64.5) 29 (80.5) 88 (74.5) 0.156
IMW, internal medicine ward; ICU, intensive care unit.
Table 4
Univariate analysis of risk factors for 30-day mortality
Characteristics All patients 30-day outcome p-Value
(n = 106) Survival Death
Age, years, median (IQR) 70 (61–80) 66 (54–81) 71.5 (62.5–80) 0.223
Sex, male, n (%) 60 (56.6) 23 (54.8) 37 (57.8)
Assistance in ADL, n (%) 58 (54.7) 22 (52.4) 36 (56.3) 0.695
Nursing home prior to hospitalization, n (%) 34 (32.1) 14 (33.3) 20 (31.3) 0.822
BMI, kg/m2, mean (SD) 25.6 (5.8) 26.1 (6.5) 26.3 (6.5) 0.324
Charlson score, mean (SD) 3.7 (2.2) 3.4 (2.5) 3.9 (2) 0.083
White blood cells, 109/l , mean (SD) 14.1 (10.9) 11.9 (8.6) 15.5 (12) 0.106
Central line catheter, n (%) 61 (60.4) 21 (55.3) 40 (63.5) 0.413
Prior hospitalization in 90 days, n (%) 61 (57.5) 27 (64.3) 34 (53.1) 0.256
Ward
Internal medicine ward, n (%) 51 (48.1) 19 (37.3) 32 (62.7) <0.01
General surgery, n (%) 31 (29.2) 19 (61.3) 12 (38.7)
Intensive care unit, n (%) 24 (22.6) 4 (16.7) 20 (83.3)
Antifungal therapy, n (%) 69 (65.1) 33 (78.6) 36 (56.3) 0.018
Time to antifungal therapy, n (%) <0.01
Adequate therapy within 48 h 37 (34.9) 12 (28.6) 25 (39.1)
Adequate therapy after 48 h 33 (31.1) 21 (50.0) 12 (18.8)
No treatment 36 (34) 9 (21.4) 27 (42.2)
Removal of indwelling catheters, n (%) 39 (36.8) 22 (52.4) 17 (26.6) <0.01
IQR, interquartile range; ADL, activities of daily living; BMI, body mass index; SD, standard deviation.
Table 5
Multivariate model of risk factors for outcome in 106 patients considered in the
study
Risk factors Hazard
ratio
95% Conﬁdence
interval
p-Value
Lower
limit
Upper
limit
Ward
IMWs vs. surgical wards 2.89 0.79 10.89 0.116
IMWs vs. ICU 0.57 0.2 1.6 0.3
Antifungal therapy
Adequate >48 h vs. adequate 48 h 3.7 1.14 12.5 <0.05
No treatment vs. adequate 48 h 1.16 0.31 4.34 0.823
Removal of indwelling catheters 0.35 0.11 1.05 0.062
IMW, internal medicine ward; ICU, intensive care unit.
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study by Bassetti et al. were found.4 In a multivariate analysis,
adequate antifungal therapy within 48 h was the only signiﬁcant
predictor of survival.
In a recent multicenter study conducted in Italy and Spain, an
unusually large proportion (49.6%) of candidemia episodes were in
IMW patients. Another major ﬁnding of this study was the
signiﬁcantly higher mortality rate for candidemia in patients
admitted to hemato-oncology wards and IMWs compared with theTable 6
Resistance to antifungal therapy during the study period
Antifungal agent Overall C. albicans C. glabrata 
n = 118 n = 52 (%) n = 28 (%) 
Amphotericin B 0.8 1.9 0 
Fluconazole 6.8 3.8 10.7 
Itraconazole 15.3 0 60.7 
Voriconazole 0.8 0 3.6 
Anidulafungin 1.7 0 0 
Caspofungin 2.5 0 0 other wards (44.4% versus 35.4%). In a second study from Italy, the
prevalence of candidemic patients hospitalized in IMWs was 38%,
and the mortality rate was signiﬁcantly higher in patients admitted
to IMWs compared with the other wards (50.4% vs. 36.1%,
p = 0.008), suggesting that factors such as age and multiple co-
morbidities made a major contribution towards poor outcomes in
these patients.13 The ﬁndings of the present study emphasize the
need for further research evaluating a new and more accurate risk
score for candidemia in the IMW population.
Important limitations of this study include its retrospective
cohort design, which lacks the quality of a randomized controlled
trial. Due to the small sample size and in order to avoid selection
bias, all 118 consecutive incident cases diagnosed with candidemia
were included. Only the infection characteristics and mortality
data were obtainable for 12 patients, and these patients were not
included in the descriptive and multivariate analysis. Finally, as a
single center study, the generalizability of the results is limited to
similar centers. A larger, multicenter database will increase the
signiﬁcance of the results and the study’s external validity.
Future studies should focus on comparing IMW patients with
candidemia to a control group of IMW patients without
candidemia to further support the present study ﬁndings, and
also on formulating a more accurate risk score for this population,
taking into account their special characteristics.C. parapsilosis C. tropicalis C. krusei Others
n = 18 (%) n = 16 (%) n = 1 (%) n = 3 (%)
0 0 0 0
11.1 0 100 0
5.6 0 0 0
0 0 0 0
11.1 0 0 0
11.1 0 0 33.3
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Appendix A
A.1. Microbiological methods
Isolates were identiﬁed using several tests, including CHRO-
Magar Candida and the germ tube assay for all suspected Candida
albicans isolates, VITEK II, and the API ID 32 C (bioMe´rieux, Marcy
l’Etoile, France). The in vitro activity of the antifungal agents was
measured using the Etest (AB Biodisk, Solna, Sweden) in
accordance with the manufacturer’s instructions. A suspension
with a turbidity of 0.5 McFarland was inoculated onto plates
containing RPMI + 2% glucose + MOPS medium. Plates were
incubated for 24 h at 35 8C in a moist incubator. For Candida
glabrata, the incubation time was 48 h. This method has shown
excellent correlation with other methods.22 Candida parapsilosis
ATCC 22019 and Candida krusei ATCC 6258 were used for quality
control. Susceptibility criteria were those given in the manufac-
turer’s guidelines (Etest; AB Biodisk, Solna, Sweden). The guide-
lines are based on experience with mucosal infections, but are
consistent with the limited data available for invasive infections
due to Candida species. C. krusei are assumed to be intrinsically
resistant to ﬂuconazole; thus interpretation was not done using
these guidelines.
Due to the lack of deﬁned breakpoints for amphotericin and
voriconazole, a susceptibility breakpoint of 1.0 mg/ml was
employed for both drugs.23
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